晶泰科技：ReviR创新药RTX-117获中美临床批件
Xin Lang Cai Jing·2026-01-14 01:29
Core Viewpoint - Jingtai Technology announced that its incubated company ReviR has received dual IND approvals in China and the US for its innovative drug pipeline RTX-117, resulting in milestone payments totaling tens of millions of Hong Kong dollars to Jingtai Technology [1] Group 1 - ReviR will continue the clinical development of RTX-117 following the IND approvals [1] - Jingtai Technology has the right to participate in revenue sharing from the sales and subsequent licensing of the RTX-117 pipeline [1]